These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Process development and preclinical evaluation of a major Somanathan A; Mian SY; Chaddha K; Uchoi S; Bharti PK; Tandon R; Gaur D; Chauhan VS Front Immunol; 2022; 13():1005332. PubMed ID: 36211427 [No Abstract] [Full Text] [Related]
10. Identification and Immune Assessment of T Cell Epitopes in Five Kotraiah V; Phares TW; Terry FE; Hindocha P; Silk SE; Nielsen CM; Moise L; Tucker KD; Ashfield R; Martin WD; De Groot AS; Draper SJ; Gutierrez GM; Noe AR Front Immunol; 2021; 12():690348. PubMed ID: 34305923 [TBL] [Abstract][Full Text] [Related]
11. Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations. Azasi Y; Gallagher SK; Diouf A; Dabbs RA; Jin J; Mian SY; Narum DL; Long CA; Gaur D; Draper SJ; Fay MP; Miller LH; Miura K Sci Rep; 2020 Jul; 10(1):11802. PubMed ID: 32678144 [TBL] [Abstract][Full Text] [Related]
12. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. Williams AR; Douglas AD; Miura K; Illingworth JJ; Choudhary P; Murungi LM; Furze JM; Diouf A; Miotto O; Crosnier C; Wright GJ; Kwiatkowski DP; Fairhurst RM; Long CA; Draper SJ PLoS Pathog; 2012; 8(11):e1002991. PubMed ID: 23144611 [TBL] [Abstract][Full Text] [Related]
13. Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex. Williams BG; King LDW; Pulido D; Quinkert D; Lias AM; Silk SE; Ragotte RJ; Davies H; Barrett JR; McHugh K; Rigby CA; Alanine DGW; Barfod L; Shea MW; Cowley LA; Dabbs RA; Pattinson DJ; Douglas AD; Lyth OR; Illingworth JJ; Jin J; Carnrot C; Kotraiah V; Christen JM; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Skinner K; Miura K; Long CA; Higgins MK; Draper SJ Nat Commun; 2024 Jun; 15(1):4857. PubMed ID: 38849365 [TBL] [Abstract][Full Text] [Related]
14. The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target. Ragotte RJ; Higgins MK; Draper SJ Trends Parasitol; 2020 Jun; 36(6):545-559. PubMed ID: 32359873 [TBL] [Abstract][Full Text] [Related]
15. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771 [TBL] [Abstract][Full Text] [Related]
16. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. Healer J; Thompson JK; Riglar DT; Wilson DW; Chiu YH; Miura K; Chen L; Hodder AN; Long CA; Hansen DS; Baum J; Cowman AF PLoS One; 2013; 8(9):e72504. PubMed ID: 24039774 [TBL] [Abstract][Full Text] [Related]
17. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Ord RL; Caldeira JC; Rodriguez M; Noe A; Chackerian B; Peabody DS; Gutierrez G; Lobo CA Malar J; 2014 Aug; 13():326. PubMed ID: 25135070 [TBL] [Abstract][Full Text] [Related]